Nortran Pharmaceutical -NRT.V Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: SOROS who wrote (882)	6/24/1998 1:33:00 AM
From: Wisee	Read Replies (1) of 1185

To All, A friend of mine brought to my attention a stock called Medco Research (MRE on AMAX). Medco is working on drug that helps patients after a heart attack. Their drug is presently in Phase III trials. Medco's market cap is $243 million US or $350 million CAN. If Hoffman LaRoche exercise their option on Nortran's antiarrhythmic compounds, I would suspect that they would fast track the tests to Phase III within 36 months. Nortran would trade at $10+, similar to what Medco's market cap. is today. We also have to remember that Nortran has several other potential "blockbuster" drugs in its pipeline for near term commercialization. Short term pain, long term gain!! Wisee

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next